Pharmacokinetics and Tolerability of LC28-0126, a Novel Necrosis Inhibitor, After Multiple Ascending Doses: A Phase I Randomized, Double-blind, Placebo-controlled Study in Healthy Male Subjects

Eunwoo Kim,Inyoung Hwang,SeungHwan Lee,Jaeseong Oh,Hyewon Chung, Myungwon Jin,Soon Ha Kim,Kyung-Sang Yu

Clinical Therapeutics（2020）

引用 3|浏览10

暂无评分

摘要

•LC28-0126 is a necrosis inhibitor under clinical development.•LC28-0126 shows acceptable tolerability after multiple intravenous doses.•LC28-0126 shows rapid distribution and dose-proportional systemic exposure.

查看译文

关键词

clinical trials,LC28-0126,pharmacokinetics,Phase I,tolerability

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要